3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Melanoma
1
Kidney Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Interventions
Filgrastim
15
Carboplatin
10
Ifosfamide
9
Doxorubicin
9
Cyclophosphamide
9
Peripheral Blood Stem Cell Transplantation
7
pembrolizumab
6
Radiotherapy
6
Gemcitabine
6
Temozolomide
5
Etoposide
5
Cisplatin
5
Paclitaxel
4
Docetaxel
4
Amifostine
4
aldesleukin
3
aflibercept
3
Trastuzumab
3
Specimen Handling
3
Radiosurgery
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Biopsy
3
tislelizumab
2
sodium thiosulfate
2
selinexor
2
pazopanib
2
palbociclib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Genetic Counseling
×
Gynecologic
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled